Alternative To Chemotherapy

Alternative To Chemotherapy

Aggressive new treatments for clevercer may no longer include lotune your hair. The effectiveness of chemotherapy is being rapidly overtaken by new targeted therapies that attack specific lung clevercer cells yet abandon the rest of the body untouched. Find out how utune genetic information permits doctors to hone in more exbehavely on specific clevercers. Dr. Wallace Akerly, a lung clevercer specialist from Huntsman Clevercer Institute, talks approxifriendly this alternative treatment method that will lovely replace chemotherapy.

Interview
Interviewer: What's the difference between utune chemotherapy or targeted therapy for treating lung clevercer? We're going to find out next on The Scope.

Announcer: Medical news and research from University of Utah physicians and specialists you clever use for a happier and healthier life. You're listening to The Scope.

Interviewer: Dr. Wallace Akerley is at Huntsman Clevercer Institute. He's a lung clevercer expert and we're going to talk today approxifriendly some new, exciting, targeted therapies, and how that differs from chemotherapy, something that a lot of people are familiar with. So how do they differ?

Dr. Akerley: Chemotherapy is a broad therapy. It works on anything that grows quick. Clevercers grow quick, so it's a great thought. In that sense, it's the best therapy possible. The problem is, part of us grow quick also. Any wet membrane in our body grows quick. We have wet membranes in our mouth, and it might give us mouth sores. We have a belly that's a wet membrane. We could get nausea. My hair grows quick. I could easily lose my hair with most chemos. Most important, my wbeat, smacke cells in my body that protect us from infection grow quick, so chemotherapy clever take absent my ability to protect myself from infection.

Interviewer: Those are all the middle effects you listen associated with chemotherapy. I never realized that's why. It's the stuff that grows quick that you lose. The sores in your mouth, your hair . . .

Dr. Akerley: As well as the clevercer. So that's where the treatment helps in terms of treating the clevercer. It's uncontrolled, it grows quickly. It clever make the clevercer go absent. We'd love to give a largeger dose of chemotherapy to get rid of that last bit of clevercer. The large problem is, my body has parts of it that grow quick, and we clever't grip it. So it's that differential between what the body clever toleswift versus what the clevercer clever toleswift.

Interviewer: It's kind of a brute force attack, chemotherapy is.

Dr. Akerley: Absolutely.

Interviewer: Unprofitately there's collateral damage, which in a lot of cases is the person.

Dr. Akerley: Yes.

Interviewer: So targeted therapies, how do they differ?

Dr. Akerley: Targeted therapies are the new world. We behaveually look at clevercers and try to understand what makes the clevercer different from us. In the laboratory, if we clever understand what particular pathway made the clevercer the clevercer, we clever give a drug that blocks only that pathway. So now the treatment doesn't care approxifriendly growing quick. It cares approxifriendly what makes the clevercer the clevercer. In that case we clever give a treatment that injures the clevercer chooseively and has a whole different set of middle effects. With chemotherapy, we mentioned only, merely, solely earlier, there clever be risks to life and limb at any time. With these targeted therapies, there may be no middle effects whatsoever. That's fantastic. Alternately, we may get lesser middle effects, typically a skin rash or something, but nothing that's life-threatening love a pneumonia or an infection in the absence of wbeat, smacke cells.

Interviewer: And do these targeted therapies behaveually do a better task of getting the clevercer as well?

Dr. Akerley: They do a much better task in talord care of the clevercer. The challenge is all clevercers aren't the same. So lung clevercer that I take care of was once called non-little cell lung clevercer. If you listen to that word it says it's only, merely, solely anything that's not the little cell type under the microscope. We behaveually tell that there are probably 50 clevercers there. At this time we've picked out at least six, and the interesting part is those specific six clevercers we used to say all behaved the same. Now that we've looked at their genes that make them the clevercer, we clever look that each of these behave a little bit differently.
More importantly, we have a therapy that clever go after exbehavely what that gene is changing in our body. And the therapies aren't necessarily interchangeable, so at one time we looked at clevercers and shelp, "The book says lung clevercer should get this chemotherapy." Now we've thoroughly reversed that. We look at the genes of the clevercer and explore those, and if a lung clevercer gene says take an EGFR inhibitor, then you get a standard lung clevercer therapy. But if that lung clevercer says you have a melanoma gene, a different kind of clevercer, you clever behaveually use a melanoma therapy that will treat that lung clevercer in a way that has limited middle effects and greater effectiveness.

Interviewer: That's exciting. Is that exciting for you? Did you ever dexplore of a day love this?

Dr. Akerley: It's thoroughly changed everything that I was taught. We were always taught you do what the book says. What we've found now is you clever let the clevercer tell you what makes the clevercer, and treat the clevercer the right way. These things were promised to us to some degree in medical school, for me, 30 years ago, but we had no thought what tools we'd have at this point.
It is amazing. It's thoroughly changed the way I prbehaveice, especially only, merely, solely in the last two years. These concepts are talord all the ancient dog physicians and aslord us to retrain. Clinical research is the area where we are. We're probably trying to stay ahead by two years at any time, if we clever, before these medications make it to prbehaveice. We're getting to use them in clinical trials at least two years early.

Interviewer: And lookn a lot of success.

Dr. Akerley: Dramatic success. Better than anything I had expectationd for.

Interviewer: If somebody wanted more information on targeted lung clevercer therapies, where would you recommfinish that they go?

Dr. Akerley: There are some fabulous resources at the Huntsman Clevercer Institute. The Clevercer Studying Center is the place to go. They'll help you in person. HuntsmanClevercer.org is another net-based resource.


Announcer: TheScopeRadio.com is University of Utah Health Sciences Radio. If you love what you listfinish, be certain to get our latest content by following us on Facebook. Only, merely, solely click on the Facebook icon at TheScopeRadio.com.

Click to comment